SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales for the March 2024 quarter moved up 28.76% to Rs. 3992.43 millions as compared to Rs. 3100.64 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2024 is Rs. -1149.69 millions as compared to Net Loss of Rs. -1438.35 millions of corresponding quarter ended March 2023 Operating profit Margin for the quarter ended March 2024 improved to 376.31% as compared to -49.43% of corresponding quarter ended March 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 3992.43 3100.64 28.76 14421.68 10724.32 34.48 14421.68 10724.32 34.48
Other Income 70.37 37.88 85.77 303.86 418.48 -27.39 303.86 418.48 -27.39
PBIDT 376.31 -49.43 -861.30 813.05 -510.65 -259.22 813.05 -510.65 -259.22
Interest 17.58 29.32 -40.04 104.20 93.80 11.09 104.20 93.80 11.09
PBDT -897.50 -1155.17 -22.31 132.77 -1731.09 -107.67 132.77 -1731.09 -107.67
Depreciation 252.19 283.18 -10.94 1054.58 1059.79 -0.49 1054.58 1059.79 -0.49
PBT -1149.69 -1438.35 -20.07 -921.81 -2790.88 -66.97 -921.81 -2790.88 -66.97
TAX 0.00 0.00 0.00 0.00 206.12 0.00 0.00 206.12 0.00
Deferred Tax 0.00 0.00 0.00 0.00 206.12 0.00 0.00 206.12 0.00
PAT -1149.69 -1438.35 -20.07 -921.81 -2997.00 -69.24 -921.81 -2997.00 -69.24
Equity 140.81 140.81 0.00 140.81 140.81 0.00 140.81 140.81 0.00
PBIDTM(%) 9.43 -1.59 -691.24 5.64 -4.76 -218.40 5.64 -4.76 -218.40

Unichem Lab Share Price

350.85 4.85 (1.40%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×